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Halogenating enzymes are able to introduce halogen substitu-
ents under ambient conditions using non-hazardous reagents
with intriguing selectivity, which is highly desired in green
chemistry. Although C  H functionalization such as halogenation
is a well-known transformation in synthetic chemistry, the
selective incorporation of halogens using conventional chemical
approaches often remains challenging. Therefore, enzyme-
based strategies have been emerging as valuable alternatives in
recent years. Inspired by manifold developments of enzymatic
halogenation, this review focuses on advances of halogenating
enzymes and their application with particular emphasis on FAD-
dependent halogenases (FDHs). Catalytic strategies, application
scope and engineering of FDHs are outlined pointing to the
increasing utility of halogenases as promising biocatalysts.
Current limitations as well as potential future developments of
their synthetic utility are being discussed.
1. Introduction
1.1. Occurrence and Value of Halogenated Compounds
Halogenation attracts increasing interest from academia and
industry as halogen substituents significantly impact the
function of organic compounds and open up a vast repertoire
of subsequent functionalization strategies. Up to now over 5000
natural products have been identified containing a halogen
substituent that often is decisive for biological activity (Fig-
ure 1).[1]
For instance, the halogen motif represents a valuable
strategy for improvement of bioactivity and bioavailability in
pharmaceuticals. In view of their optimal efficacy organo-
halogens constitute over 34% of the registered drugs and
continuously attract widespread attention for improving bind-
ing affinity or optimization of the ADME/T parameters (absorp-
tion, distribution, metabolism, excretion, and toxicity).[2] Today,
around two thirds of all known agrochemicals contain halogen-
substituted aryl and hetaryl moieties which underlines the
widespread utility and increasing demand for these versatile
compounds.[3,4]
Apart from their pharmacological value, the synthetic
interest in halogenated compounds lies in their ability to serve
as building blocks and starting material for a broad array of
synthetic transformations. In particular, a large range of
valuable products is made accessible from aryl halides by
making use of metal-catalyzed cross-coupling reactions.[5]
Generally, C  H functionalization using halogenation is,
therefore, an essential transformation to assemble complex
organic scaffolds. However, activation of non-activated carbons
often requires noble metal catalysts, toxic reagents and
frequently proceeds under harsh conditions. Less activated
positions are difficult to address while considerable amounts of
by-products and waste being produced must not be
neglected.[6] The desired organohalogens can be accessed via a
wide range of strategies, including radical-based mechanisms,
electrophilic addition or electrophilic aromatic substitution
(SEAr). SEAr is a widely-applied reaction type for arene
functionalization that is of major importance for the synthesis
of bulk and fine chemicals, yet control of regioselectivity and
introduction of the halogen atom at electronically and mecha-
nistically disfavored positions remain challenging.[7–9] In recent
years, identification, application and engineering of halogen-
ases has attracted growing interest with an increasing signifi-
cance for site-selective C  H functionalization.[10,11] The broad
utility of halogenated compounds in synthesis has promoted
extensive efforts in development and optimization of alterna-
tive routes towards halogenation providing a safe and selective
approach for the synthesis of haloarenes under benign reaction
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Figure 1. Selection of halogenated secondary metabolites as representatives
for chlorinated, brominated, or iodinated natural products as well as the
fluorinated synthetic antibiotic (ciprofloxacin) and herbicide (aminocyclopyr-
achlor).
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conditions. In living systems, a diverse array of halogenases
catalyzes the incorporation of halogens. Biohalogenation occurs
on a large variety of organic scaffolds, for instance aliphatic
carbons, olefins as well as aromatic and heterocyclic rings.[9]
2. Halogenases: A Diverse Enzyme Class
2.1. Subclasses of Halogenating Enzymes
Halogenases form a heterogenous enzyme class and can be
divided into O2-dependent halogenases, haloperoxidases as
well as fluorinases (Table 1).[16]
2.2. Fluorinating Enzymes
Most frequently, chlorine and bromine are found in natural
products, whilst iodinated or fluorinated natural compounds
are more rare.[19] Only a few fluorinated metabolites have been
identified so far as chemical properties and natural abundance
of fluorine restrict the biosynthesis and biochemical significance
of organofluorine compounds. Even though fluoride is highly
abundant in the earth‘s mantle and crust, its occurrence in the
ocean is very low compared to chloride and bromide (F  =
1.3 ppm; Cl  =18800 ppm; Br  =67 ppm).[19–21] In contrast to the
oxidative mechanism of the C  Cl, C  I and C  Br bond formation,
enzymatic C  F bond formation is performed by nucleophilic
substitution. Apart from fluorine’s high electronegativity that
prevents an oxidative mechanism, the difficulty of desolvating
the fluoride ion in aqueous media, which is an essential feature
to act as a naked nucleophile, as well as the toxicity of
accumulating fluorinated metabolites in the producer organism
are considered as reasons for the limited amount of known
fluorinated metabolites.[9] Only a few native fluorinating
enzymes have been characterized in detail so far, such as the
fluorinase FlA from Streptomyces cattleya, catalyzing nucleo-
philic attack of fluoride to S-adenosyl-l-methionine (SAM), thus
generating 5’-fluorodeoxyadenosine (5’-FDA) and l-methionine
as a byproduct (Scheme 1a).[22,23] The biotechnological applica-
tion of fluorinases is limited by the organism’s sensitivity
towards fluoride ions and thus hinders large-scale fermentation
of fluorinated metabolites. Nevertheless, engineering ap-
proaches of FlA into a related host organism demonstrated the
successful production of fluorinated pharmaceutically relevant
molecules. A striking feature is that fluorinases are capable of
selectively introducing the isotope 18F into metabolites which
serves as a probe for radiolabeling in positron emission
tomography (PET). Simply by choosing 18F as a fluoride source
the desired isotope can be introduced into the target molecule
albeit requiring high stoichiometric quantities of fluorinase
compared to 18F.[23]
2.3. Haloperoxidases: Heme-Dependent and
Vanadium-Dependent Enzymes
Haloperoxidases are subdivided into heme-dependent and
vanadium-dependent enzymes that follow an oxidative reaction
pathway and rely on H2O2 as oxidizing agent.
The generated iron(IV)-oxo species (Scheme 1b) or vanadate
intermediate (Scheme 1c) reacts with chloride, bromide or
iodide forming diffusible hypohalous acid (HOX) that is released
into the medium and serves as halogenating agent in the
exterior.[9] As a consequence, HOCl reacts with electron-rich
compounds in a purely chemical, nonspecific manner, thus
addressing multiple halogenation sites and lacking
selectivity.[13,24,25]
2.4. Mechanism and Engineering of Non-Heme-Iron
Dependent Halogenases
O2-dependent halogenases require oxygen as a reducible co-
substrate and are subdivided into non-heme-iron-dependent
halogenases and flavin-dependent halogenases.[9] Non-heme
iron-dependent halogenases follow a radical-based mechanism
coupled to the decarboxylation of α-ketoglutarate (α-KG). This
induces formation of an Fe(IV)-oxo intermediate that acts as a
hydrogen-abstracting species and enables the halogenation of
non-activated, aliphatic C  H sites (Scheme 1d).[9,16,27–29]
These enzymes predominantly act on substrates tethered to
acyl carrier proteins, such as SyrB2 from Pseudomonas syringae
pv. syringaeB301D that catalyzes the chlorination of threonine
in syringomycin E biosynthesis.[30] Interestingly, characterization
of WelO5 revealed that this non-heme-iron dependent halogen-
ase also accepts free small-molecule substrates, as the latter
catalyzes the chlorination of aliphatic carbons in fischerindoles.
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Structural analysis of WelO5 provided further details on the
reaction mechanism suggesting the migration of the Fe-oxo
species upon decarboxylation of α-KG.[27] Even though WelO5
has a limited substrate scope, its close homologue AmbO5, to
which it shares 79% sequence identity, was shown to chlorinate
several structurally distinct ambiguine, fischerindole, and hapal-
indole alkaloids (Figure 2a–c). AmbO5’s significantly broader
substrate scope is related to its C-terminal region that contains
Table 1. List of different halogenase subclasses and their associated characteristics.
Enzyme class Subclass
(reaction
type)
Co-substrate Halogenating species/specificity Substrate re-
quirements
Example
Haloperoxid-
ase
Heme-de-
pendent
(oxidative)
H2O2/halide Diffusible HOX;
nonspecific halogenation
Aromatic and
electron rich
Halogenase from Caldariomyces fumago[12]
Vanadium-
dependent
(oxidative)
H2O2/halide Diffusible HOX;
nonspecific halogenation
Aromatic and
electron rich
Fungal chloroperoxidase (V–CPO) from Curvu-
laria inaequalis[13]; Vanadium haloperoxidase
genes from Streptomyces sp. CNQ-525[14]
O2-depend-
ent
halogenase
Non-heme,
Iron-depend-
ent
(radical)
O2 /halide/α-
ketoglutarate
Halogen radical species; regio-and
stereospecific halogenation on car-
rier-bound and free substrates
Non-activated
carbon centres,
aliphatic moieties
SyrB2 from Pseudomonas syringae pv. syringae
B301D[15]; WelO5 from H. welwitschii UTEX
B1830[16]
Flavin-de-
pendent
(oxidative)
O2/Cl
  or
Br  /FADH2
HOCl trapped in active site; regio-
specific halogenation on free and
carrier bound substrates
Aromatic and
electron rich
PrnA from Pseudomonas fluorescens[17]
Fluorinases (nucleophilic) SAM/F  Nucleophilic halide Electrophilic,
good leaving
group
Fluorinase FlA from Streptomyces cattleya[18]
Scheme 1. a) Enzymatic fluorination from the biosynthetic pathway of fluoroacetate and 4-fluorothreonine in Streptomyces cattleya. The fluorinase catalyzes
nucleophilic attack of F  on SAM to produce 5’-FDA, thereby exploiting l-Met as an excellent leaving group for an SN2-type reaction.
[23] b) Catalytic mechanism
of heme-dependent haloperoxidases: The ferric ground state is constituted of a water bound iron(III)-heme complex. (i) The substrate H2O2 enters the active
site and displaces the distal water thereby forming the hydroperoxo intermediate Fe(III)  OOH (compound 0). (ii) The reactive iron(IV) oxo species (compound
I) is generated by a heterolytic cleavage of the O  O bond initiated by preceding protonation of compound 0. (iii) Compound I oxidizes a halide anion (X  ) and
releases hypohalite (OX  ). (iv) The ferric ground state is regenerated by addition of water.[26] c) Catalytic cycle of vanadium-dependent haloperoxidases: (i) The
substrate H2O2 coordinates to the vanadium center leading to loss of H2O and formation of a peroxo-vanadium intermediate. (ii,iii) The halide anion (X
  ) is
being oxidized, resulting in the formation of hypohalous acid (HOX). The oxidation state of vanadium is maintained throughout the catalytic cycle.[26] d)
Catalytic cycle of non-heme-iron-dependent halogenases based on the crystal structure of WelO5: (i) O2-dependent decarboxylation of α-KG results in
formation of an iron(IV)oxo species that was presumed to relocate into the ligand plane. (ii) Radical abstraction of a hydrogen atom from the substrate. (iii)
Recombination of the substrate radical with the halogen radical gives rise to the chlorinated product.[27]
ChemCatChem
Reviews
doi.org/10.1002/cctc.202000531
4453ChemCatChem 2020, 12, 4450–4470 www.chemcatchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Freitag, 11.09.2020
2018 / 173127 [S. 4453/4470] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
18 of the 32 differing amino acid residues compared to WelO5.
Generation and characterization of WelO5/AmbO5 chimera
further underlined the relevance of a signature C-terminal
sequence motif that confers substrate promiscuity and
specificity.[16,27] Recent identification of the third WelO5-type
protein, WelO5*, sharing 95% sequence identity to WelO5,
revealed an enhanced specificity for substrates that were
merely poorly processed by WelO5. As previously reported for
AmbO5, WelO5*’s C-terminal sequence motif harboring 11
varied amino acids is proposed to be the origin for the
observed substrate specificity and enhanced activity for
selected substrates compared to WelO5.[31] Hayashi et al. aimed
to expand the substrate scope of WelO5* towards a pharma-
ceutically relevant martinelline-derived fragment that was
neither accepted by WelO5 nor AmbO5 (Figure 2d). Based on
low promiscuous activity of WelO5* a structure-guided evolu-
tion approach was pursued. After two rounds of mutagenesis
two regio-complementary WelO5* single mutants were identi-
fied addressing different positions of the aliphatic cycle. The
evolved variants were endowed with increased chlorination
activity for the target substrate whereas the undesired hydrox-
ylation activity observed for the WT enzyme was significantly
reduced or even diminished. Thereby their effort provides the
first example of enzyme engineering of a non-heme iron-
dependent halogenase amenable for halogenation of non-
activated carbons.[32] Very recently Duewel et al. made use of
structure-guided evolution to evolve Wi-WelO15 where smart
library design yielded an improved mutant capable of address-
ing non-activated C  H bonds for a panel of non-native hapal-
indoles. In light of these recent engineering efforts, it is
apparent that Fe/α-KG dependent halogenases gain increasing
importance due to their ability to address non-activated
carbons. It will be of particular interest how the scope of these
enzymes will be further broadened in future.[33]
3. Flavin-Dependent Halogenases
Among the halogenating enzymes, FAD-dependent halogen-
ases (FDHs) currently provide suitable candidates for synthetic
use. They are particularly suitable for halogenation of electron
rich arenes owing to their impressive selectivity in conjunction
with benign reaction conditions. These biocatalysts merely
require halide salts, molecular oxygen and reduced flavin-
adenine dinucleotide (FADH2) to catalyze electrophilic aromatic
substitution. Owing to their facile handling at room temper-
ature, neutral pH and high functional group tolerance without
requiring activating or protecting groups, enzymatic halogen-
ation emerged as a versatile methodology for synthetic
purposes.[34]
During the past decade extensive research was in particular
carried out by the groups of van Pée and Walsh to gain deeper
insight into FDHs. Despite recent efforts to improve their in vitro
compatibility, FDHs still suffer from severe drawbacks such as
low activity, insufficient stability and their restriction to
relatively electron rich aromatic compounds. However, advan-
ces in the field of halogenase engineering and subsequent
integration into chemical transformations corroborated their
versatility as environmentally friendly biocatalysts.
3.1. Pioneering Identification and Characterization of
Flavin-Dependent Tryptophan Halogenases (Trp-FDHs)
In 2000, van Pée and coworkers isolated and characterized
PrnA, the first member of the tryptophan (Trp) halogenase
family, from Pseudomonas fluorescens.[17] Subsequently, further
Trp-FDHs, such as Trp 7-halogenase RebH from Lechevalieria
aerocolonigenes,[35] the Trp 5-halogenase PyrH from Streptomy-
ces rugosporus,[36] and the Trp 6-halogenase Thal from Strepto-
myces albogriseolus[37] were identified.[38,39] Moreover, SttH from
Streptomyces toxytricini NRRL 15443,[40] thermophilic Th-Hal from
Streptomyces violaceusniger,[41] thermophilic BorH from uncul-
tured bacteria[42,43] as well as KtzR from Kutzneria sp. 744[44] also
act as Trp 6-halogenases. Noteworthy, KtzR and KtzQ are acting
in a tandem manner and catalyze the regiospecific dichlorina-
tion of l-Trp yielding l-6,7-dichloro-Trp. Both enzymes act
sequentially on free l-Trp with the first chlorination introduced
by KtzQ followed by KtzR that exhibits a 120-fold preference for
l-7-Cl-Trp. In 2019, Domergue et al. reported the identification
of XszenFHal, a novel Trp-5 halogenase from X. szentirmanii.[45]
For its identification a collection of putative enzymes homolo-
gous to halogenases was generated based on the protein
sequence of 22 known FDHs and a reduced number of 148
enzymes tested against a panel of different aromatic substrates.
Here, only XszenFHal, sharing 60% identity with Trp 5-
halogenase PyrH, confirmed halogenation activity on substi-
tuted Trp, indole and indole derivatives. Though halogenation
exclusively occurred at C5, a clear enantioselectivity was noted
Figure 2. Selection of small-molecule substrates (a–c) of non-heme-iron
dependent halogenases WelO5 and AmbO5. In addition, two engineered
variants of WelO5* regioselectively chlorinate a martinelline-derived frag-
ment (d) at distinct positions.
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for l-Trp. In accordance to other Trp halogenases XszenFHal
prefers chlorination over bromination, whereas no incorpora-
tion of iodide was observed.
With the exceptions of Bmp2 and Bmp5[46] which only
accept bromide but not chloride, most FDHs described so far
are able to use both halides. Owing to increased reactivity in
cross-coupling reactions, aryl bromides have a higher relevance
for chemoenzymatic synthesis compared to their chlorinated
analogues. However, chlorination prevails over bromination.
Enzymatic bromination is possible for promiscuous enzymes if a
large excess of bromide is supplied. However, even in such
cases chlorination is commonly observed as a side reaction
because contamination with small amounts of chloride is
inevitable in enzyme preparation. For a long time it was
assumed that neither fluoride nor iodide are competent for
halogenation, though Bmp5 is reported to catalyze iodination
of its substrates in vivo.[35,36,46] However, the group of Goss
recently reported the identification of a iodinating viral FDH
exhibiting a natural preference for iodination in vitro.[47]
3.2. Crystal Structure of FDHs
The X-ray single crystal structure of the Trp 7-halogenase PrnA
involved in pyrrolnitrin biosynthesis was the first one to be
published.[48] As has been observed also for other Trp halogen-
ases, PrnA forms a dimer in the crystal consisting of two
pyramid-shaped monomers (Figure 3; Figure 4).[41,49–53] Each
monomer contains a variable pyramidal module and a con-
served-box shaped subdomain harboring the FAD-binding site
(GxGxxG motif, where “x” is any amino acid).[48,54] An additional
conserved motif of FDHs (WxWxIP) is suggested to prevent the
binding of organic substrates close to the isoalloxazine ring of
FADH2, suppressing potential monooxygenase activity.
[51,55]
Recently, the group of Goss identified another sequence motif
characteristic for halogenases, Fx.Px.Sx.G, where each “.”
represents a varying number of amino acid residues between
each conserved residue.[47,56] The overall FDH structure reveals
that the cofactor is bound in a solvent-exposed groove whereas
the substrate Trp is located in a distinct enzyme module at the
interface of the FAD-binding site and the pyramidal subdomain.
X-ray single crystal structures of PrnA,[51] RebH,[49] PyrH[50]
and Thal[57] in presence of the substrate l-Trp are in accordance
with a suggested mechanism for FDHs based on
mechanistic[52,58] and theoretical evidence[59] (Figure 4).
4. Halogenation Mechanism
4.1. General Overview on Halogenation Mechanism
As proposed by Dong et al., it is indisputable that FADH2 reacts
with molecular oxygen giving a peroxy-flavin intermediate as
shown for flavin-dependent monooxygenases. In case of
monooxygenases, this intermediate further reacts by nucleo-
philic attack of a nearby substrate resulting in oxygen
transfer.[51,60] In case of FDHs there is no space for an organic
molecule to bind adjacent to the isoalloxazine moiety. The
crystal structure of PrnA revealed that the substrate Trp and
cofactor FAD are located in different binding sites separated by
a 10 Å tunnel.[51]
This strict separation is a conserved motif observed in all
known Trp halogenases. Interestingly, the halide ion is
positioned on the opposite face of FAD near to the tunnel
entrance, allowing a nucleophilic attack on the flavin(C4a)
hydroperoxide, leading to the formation of FAD-OH and
hypochlorous acid (HOCl) (Figure 5). In contrast to haloperox-
idases, diffusion of HOCl into the surrounding medium is
prevented by the protein structure. Thus, it enters the tunnel
Figure 3. Crystal structure of Trp 7-halogenase PrnA monomer in complex
with substrate FAD, l-Trp and chloride (PDB: 2AQJ). The conserved amino
acid residues K79 and E346 are shown as purple stick models. The box-
shaped flavin binding site is shown in red, the pyramidal subdomain is
depicted as a blue ribbon model. The picture was generated and further
modified using Pymol.
Figure 4. Active-site residues of PrnA (PDB: 2AQJ) containing bound l-Trp
and highlighting crucial residues responsible for catalytic activity and
forming interactions with the substrate. The picture was generated and
further modified using Pymol.
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and is guided to the substrate binding site.[51] This tunnel
connecting the surface exposed flavin binding site with the
deeply buried substrate is lined by amino acids residues
resistant to oxidation by HOCl. The halogenating agent passes
the tunnel to the Trp-binding site. At the end of the tunnel,
HOCl is supposed to interact with a lysine residue (PrnA: K79)
highly conserved in all known FDHs. Mutation of this residue to
alanine leads to a complete loss of activity as observed for
RebH (K79),[52] PrnA (K79),[51] BrvH (K83),[61] and RadH (K74).[62] Its
role will be discussed below. E346 is closely located to K79 in
PrnA, and positioning of the substrate Trp is supported by a
hydrogen bond between the NH group of the indole ring and
the carbonyl group of peptide bond between E346 and S347.
Furthermore, the Trp amino group forms a salt bridge with the
carboxyl group of E450 and a hydrogen bond to the hydroxyl
group of Y443. The carboxyl group of l-Trp is also stabilized by
hydrogen bonds to the hydroxyl group of Y444. π-stacking
interactions of the substrate indole moiety with H101, F103 and
W455 add together to reach a rather rigid and fixed position of
Trp decisive for high regioselectivity of the halogenation
(Figure 4).
Figure 5. Proposed halogenation cycle of PrnA. (a) FADH2 is oxidized in the cofactor binding site by O2 to form the flavin hydroperoxide FAD(C4a)-OOH which
reacts with a chloride ion giving HOCl (b). The hypochlorous acid is guided via a 10 Å tunnel to the substrate binding site. (i) Subsequently, HOCl interacts
with the ɛ-amino group of K79 to form a chloroamine as proposed by Yeh et al.[52] This chloroamine is assumed to re-compose (ii), according to Flecks et al.,[58]
to HOCl that performs the electrophilic aromatic substitution. After deprotonation of the Wheland intermediate l-7-Cl-Trp is released from the active site.
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Recent approaches reported by Moritzer et al. to obtain
crystal structures of Trp 6-halogenase Thal either with bound
cofactor FAD or with bound FAD and substrate l-Trp, indicated
a decreased affinity of FAD upon substrate binding.[63] As
previously observed for RebH, binding of l-Trp probably
reduces the affinity of the oxidized cofactor that might facilitate
its release and subsequent regeneration.[49,52] Although the X-
ray singles crystal structure analyses of Thal, RebH and PyrH
hint towards negative coupling between FAD and substrate
binding, PrnA provides no hints for negative coupling between
binding of substrate and cofactor, which, therefore, cannot be
assumed as general feature of FDHs yet.
4.2. Early Investigations on the Halogenating Species
The strict conservation of the lysine residue (PrnA: K79) in FDHs
suggests that this residue adopts a crucial role in the catalytic
cycle, but its particular function has been controversially
discussed. Yeh et al. proposed that the rapid reaction of HOCl
with the ɛ-amino group of K79 leads to the formation of a long-
lived chloroamine as evidenced by radiolabeling using 36Cl. This
chloroamine could be only detected in absence of l-Trp, and
attempts to characterize this intermediate by X-ray crystallog-
raphy, NMR spectroscopy, and mass spectroscopy remained
unsuccessful. Nevertheless, remarkable stability of the enzyme-
bound chlorinating intermediate was detected in RebH, exhibit-
ing t1/2=2.3 days. Therefore, it was concluded to be the actual
halogenation species as it seems unlikely that HOCl would be
sequestered within the active site for such a long time without
diffusing away and participating on side reactions with other
biomolecules.
It was emphasized that Lys79 is positioned between the
binding pockets of FAD and Trp. In this arrangement HOCl
reaches Lys79 before encountering the substrate. Consequently,
reactive HOCl forms a covalently bound lysine chloroamine
thereby storing its oxidative potential. Furthermore, Lys79
would be ideally oriented for delivering a chloronium ion
equivalent for electrophilic aromatic substitution of the indole
ring at C7. Yeh et al. point out that – albeit exhibiting reduced
activity compared to HOCl – chloroamines are reported to be
milder and more selective towards their target.[52,64] In contrast,
Flecks et al. proposed that their electrophilicity is too weak to
achieve electrophilic substitution of the indole moiety as
quantum mechanical (QM) calculations of N-chloroamine
revealed reduced charge on the Cl atom of HOCl compared to
free HOCl. Consequently, chloroamines are weaker halogenat-
ing agents than HOCl and, therefore, not sufficient for
chlorination in this context.[58,59] Instead of involving a covalently
bound chloroamine reacting with the substrate, they proposed
that free hypochlorous acid is being reformed upon substrate
binding. Interactions of HOCl with proximal E346 are respon-
sible for proper orientation of the halide species and might
increase electrophilicity in order to allow for electrophilic
aromatic substitution. Closer mechanistic studies revealed that
one of the oxygens of the carboxyl group of E346 plays the role
of proton acceptor, while the other oxygen is involved in a
hydrogen bond interaction with the nearby NH group of Trp.
Mutation of this conserved glutamate residue in PrnA (E346Q)
causes significantly reduced activity with a decrease of kcat by
about two orders of magnitude.[51,59] As the presented assump-
tions rely on differing data no final conclusion concerning the
actual halogenation species can be drawn.
5. Classification and Examples of Unusual FDHs
5.1. FDHs Acting on Free or Carrier Bound Substrates
In general, FDHs can be subdivided into two distinct subfamilies
represented by PrnA and PrnC, respectively. The PrnA group,
comprising the most prominent members such as Trp halogen-
ases RebH,[65] PrnA,[66] and Thal[37] catalyze the halogenation of
Trp or indole derivatives, whereas the other group only accepts
more reactive phenols and pyrrole derivatives (Table 2).[50,67] The
majority of FDHs accepts non-carrier bound substrates and
probably these enzymes are involved in the biosynthetic
halogenation of secondary metabolites. In contrast, the FAD-
dependent halogenase CndH from chondrochloren biosynthesis
acts on substrates bound to a carrier protein.[68]
Table 2. Representative overview and classification of FDHs into tryptophan, pyrrole, or phenol halogenases. Classification is based on major features and
an overlap to another class is not excluded.
Flavin-dependent Halogenases
Flavin-dependent Trp Halogenases Flavin-dependent Pyrrole Halo-
genases
Flavin-dependent Phenol Halogenases
Trp 7-halo-
genase
PrnA,[17] RebH,[35] KtzQ[44] untethered
substrates
PrnC[66] Class A: untethered
substrates
Rdc2,[70] GedL,[72] RadH,[62] ChlA,[74] GsFl,[75]
Asm12,[76] AclH,[77] Nat1,[78] CazI,[79] NapH2,[14]
AcOTAhal[80]
carrier-teth-
ered sub-
strates
PltA,[69] HalbB,[71]
Clz5,[73] Bmp2[46]
Class B: carrier pro-
tein tethered sub-
strates
CndH,[68] Clo-Hal,[83] End30,[84,85] BhaA,[86,87]
Ram20,[88] ComH,[89] SgcC3,[90] Tcp12[91]
Trp 6-halo-
genase
KtzR,[44] Thal,[37] SttH,[40] Th-
Hal,[41] BorH,[42,43] AORI_
5336[82]
Trp 5-halo-
genase
PyrH,[36] XszenFHal[45] Class C: decarboxyla-
tive halogenation
Bmp5[46]
Novel Halogenases from Genome Mining
BrvH,[61] Iodinase VirX1,[47] Xcc_B100_4156, Xcc_B100_1333, Xcc_B100_4345[81]
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Structure-based sequence alignment of CndH with PrnA
and RebH revealed a comparatively low level of conservation in
the C-terminal region, allowing speculations for the altered
substrate preference. As similarly observed for other Trp
halogenases, the active site in PrnA is covered by a lid formed
from the 120C-terminal residues that closes the substrate off.[68]
Even though differences of this structural motif exist among Trp
halogenases, a conformational change occurs upon Trp binding
leading to the entire accommodation of bound Trp in the
enzyme cavity. This contrasts the active site structure of CndH
which lacks a structured C-terminal chain.[49,57] Here, the active
site remains open and solvent exposed, presenting a large non-
polar patch that probably acts as docking site of the putative
substrate carrier.[68]
5.2. FDHs Exhibiting Altered Ion Selectivity and Substrate
Scope
As disclosed by Neubauer et al., the FAD-dependent halogenase
BrvH, identified from a marine metagenome of Brevundimonas
sp. BAL3, does not accept Trp as a substrate. Comparison of its
crystal structure to other FDHs such as RebH revealed that the
BrevH substrate binding site is notably more open and lacks
side chains to position the amino and carboxylate groups of
Trp. Although the native substrate could not yet be elucidated,
halogenation of free indole in C3 position was proven. BrvH
exhibits a remarkably high preference for bromination over
chlorination, but though this unusual halide specificity could
not yet be explained.[61]
Likewise, an exclusive preference for bromination over
chlorination has also been reported for three FDHs from
Xanthomonas campestris. While exhibiting high similarity to Trp
halogenases with regard to the flavin-binding site and active
site residues, differing amino acids surrounding the halide
binding site were proposed to influence halide preference. Even
though these Xcc halogenases were originally annotated as Trp
halogenases, they do not accept Trp and exclusively brominate
substrates such as indole, 7-azaindole, 5-hydroxytryptophan
and various heterocyclic derivatives. Docking and molecular
dynamics simulations indicated that Trp – in contrast to 5-
hydroxytryptohan – is not stabilized by hydrogen bonding or
other interactions, thereby impeding the correct positioning of
Trp required for substrate binding.[81]
5.3. Identification of an Iodinating FDH
Goss and coworkers recently reported on the identification and
characterization of a remarkable marine viral FDH catalyzing the
iodination of diverse substrates in vitro.[47] Relying on the novel
motif Fx.Px.Sx.G derived from sequence alignment that was
previously overlooked, enabled the identification of VirX1 from
the cyanophage Syn10 previously known for infection of
Prochlorococcus and Synechococcus.[92] The wild type enzyme
exhibits a broad substrate flexibility, accepting a diverse array
of sterically and electronically different substrates ranging from
low to high conversions. A considerable novelty is that VirX1
shows a high and surprising preference for iodination over
bromination and chlorination, thereby being the first charac-
terized FDH with a clear natural preference for iodination
in vitro. Though iodination in most cases prevailed at the
chemically most activated position, some substrates were
halogenated at different positions than the correlates prepared
by chemical electrophilic iodination, albeit without clarifying
substitution patterns of few examples. With the presence of the
box-shaped flavin binding module and the key catalytic
residues K79 and E358 being in place, the structure of VirX1
shows many similarities to known FDHs such as PrnA and BrvH.
Still, comparison to the homodimer structure observed for Trp
halogenases, X-ray structural analysis of VirX1 revealed six
monomers in the asymmetric unit predicted to form two stable
trimeric assemblies. Furthermore, the wider opening of its
substrate binding site and the absence of the α-helical lid to
close off the active site, contrasts previous observations made
for FDHs and might explain that VirX1 accepts a broad range of
substrates and facilitates the accommodation of an iodide ion
with a larger van der Waals radius compared to bromide or
chloride (F  =1.47 Å; Cl  =1.75 Å; Br  =1.83 Å; I  =1.98 Å).[93]
The higher oxidation potential of iodide compared to bromide
or chloride favours formation of the hypohalous acid, but
further investigations concerning halide selectivity are still
required. Although the authors report higher turnover numbers
of Virx1 for iodination of an indole derivative compared to
efficiency of Trp 7-halogenase PrnA towards its natural sub-
strate, for VirX1 higher KM values were observed for the majority
of substrates tested that indicates a lower affinity. In addition, it
was previously shown that halogenase RebH is even a more
efficient biocatalyst with non-natural substrates compared to
VirX1.[94] This discrepancy is probably due to a lack of knowl-
edge about the native substrate of VirX1. Thus, it will be
interesting to resolve this question in future. Although the
physiological function of VirX1 within the virus as well as the
native substrate are still unknown, the new iodinase provides a
versatile future tool to be used in halogenation chemistry.
5.4. FDHs Acting on Peptidic Substrates
FAD-dependent MibH unveiled a novel type of halogenase as it
was shown to catalyze chlorination of Trp incorporated in a
lanthipeptide precursor synthesized ribosomally. MibH is in-
active towards free Trp. Interestingly, halogenation assays with
a panel of different NAI-107 substrate analogues revealed
MibH’s unusually narrow substrate specificity, as it was inactive
towards all tested substrates and did not tolerate even minor
modifications of the peptide (Scheme 2a). Closer investigation
on MibH’s crystal structure showed structural relationships to
FDHs, containing the conserved structural motifs WxWxIP,
GxGxxG as well as catalytically important lysine (K102) and
glutamate (E355) residues. However, MibH’s larger accessible
surface area and an expended more hydrophobic substrate
grove are likely to accommodate larger peptidic substrates.[95]
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In addition to a broad substrate scope reported for the FDH
KrmI, this enzyme is also proposed to be involved in
halogenation of peptides. Closer investigation of KrmI from the
marine sponge Theonella swinhoei WA was recently reported by
Smith et al. In vitro assays revealed that full length KrmI
preferentially chlorinates and brominates 5-hydroxytryptophan
over Trp, suggesting that this halogenase participates in
generation of halogenated keramamides. Interestingly, the C-
terminus of the protein resembles FDHs whereas the truncated
N-terminal region shows distant homology to the ThiF enzyme
family that is reported to be involved in specific binding of
peptide substrates in ribosomal peptide synthesis. Therefore,
the N-terminus may be responsible for binding of such
substrates, which might open a new field for potential
halogenase engineering.[96,97]
Recently a unique subclass of FDHs, catalyzing the iterative
late-stage halogenation of complex substrates independent of
carrier proteins was identified by Fraley et al. The fungal
halogenases MalA/MalA’ share 99% sequence identity and are
postulated to perform dichlorination and monobromination of
the free premalbrancheamide within the malbrancheamide
biosynthesis (Scheme 2b). Even though MalA’ has a similar
overall structure to bacterial FAD-dependent halogenases it
exhibits a unique Zn2+ binding C-terminus and an expansive
active site enabling the accommodation of complex
substrates.[98]
6. Strategies for the Regeneration of the Flavin
Cofactor
First investigations on PrnA revealed the necessity of a flavin
reductase activity responsible for in situ regeneration of FADH2
to enable enzymatic halogenation. A flavin reductase, e.g. PrnF
from Pseudomonas fluorescens,[17,99] RebF from Lechevalieria
aerocolonigenes[35,94] or SsuE from Thermus thermophilus[17]
catalyze reduction of FAD to FADH2 by concomitant oxidation
of NAD(P)H. Conversely, NADH regeneration can be achieved
with either an alcohol dehydrogenase (ADH),[99] phosphite
dehydrogenase (PtdH),[46,100,101] formate dehydrogenase
(FDH),[102] or glucose dehydrogenase (Scheme 3).[94,99,103]
The Lewis group demonstrated that the setup of biocata-
lytic halogenation may be simplified using a bifunctional fusion
protein consisting of FDH and flavin reductase. Here, RebH WT
or engineered variants were genetically fused by different sized
linkers, consisting of 10, 16 and 22 amino acid residues to flavin
reductases RebF or thermostable Fre from Bacillus subtilis.
Besides eliminating the need for addition of a separate flavin
reductase, this set-up should increase the cofactor regeneration
efficiency due to the close proximity of the flavin reductase and
the halogenase.
Theoretically, the reduced cofactor should easily diffuse to
the halogenase, while avoiding any undesired side reactions of
FADH2. Surprisingly, activity of the bifunctional system was
lower compared to their two-component system in vitro. Still,
higher product titers were observed for selected fusion proteins
in vivo, which shows promise for large-scale halogenation in E.
coli.[104]
Furthermore, photochemically induced regeneration of
enzyme-bound FADH2 in PyrH was reported recently.
[105] Light-
driven reduction of FAD employing ethylenediaminetetraacetic
acid (EDTA) as sacrificial reductant enables the regioselective
halogenation of Trp to 5-Cl-Trp reaching an average conversion
of 58% (Scheme 4). It is arguable if light-driven regeneration of
FADH2 occurs in an enzyme-bound state which might contrib-
ute to lower futile cycles caused by the undesired coupling
Scheme 2. a) Structure of lantibiotic NAI-107 after post-translational mod-
ifications of the precursor protein MibA. FAD-dependent MibH is only active
when Trp is embedded within the peptide substrate deschloro NAI-107.
Dha=2,3-dehydroalanine; Dhb= (Z)-2,3-dehydrobutyrine. b) Section of mal-
brancheamide biosynthetic pathway catalyzed by MalA/MalA’. Premalbran-
cheamide is proposed to be dichlorinated through an iterative mechanism.
Scheme 3. Enzymatic cofactor regeneration system enabling halogenation of
l-Trp leading to chlorination or bromination at the C5, C6 or C7-position of
the indole moiety. The cofactor FADH2 is regenerated by the flavin reductase
PrnF and NADH is provided by an alcohol dehydrogenase (RR-ADH) or any
other enzyme component capable of NADH formation (X=Cl, Br).
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reaction of FADH2 and O2 under formation of hydrogen
peroxide.[106] Apart from lowering the productivity of the
biocatalytic reaction, the latter product is also harmful to the
protein components. As demonstrated by Ismail et al., NADH
mimics can be utilized to replace enzymatic cofactor regener-
ation in biocatalytic halogenation (Scheme 5).
Here, synthetic NADH mimics, easily obtained from inex-
pensive starting materials, were stoichiometrically employed for
FADH2 regeneration and facilitated reaction set up by circum-
venting the implementation of two auxiliary enzymes. Remark-
ably, by employing NADH mimics under similar reaction
conditions and enzyme concentrations compared to enzymatic
cofactor regeneration the initial reaction rates of RebH and
PyrH were 1.3–1.9 times higher. However, reduced flavin also
reacts with oxygen in solution, thereby producing hydrogen
peroxide, compromising enzyme stability and consuming NADH
mimic in a nonproductive manner. Therefore, an excess of
NADH mimics providing superfluous FADH2 has to be avoided.
Even though NADH mimics proved their usability for scale up
reactions due to their robustness and higher stability, this set-
up is a promising future alternative for enzymatic cofactor
regeneration, which needs to be adapted to the specific
application.[107]
7. Preparative Scale Halogenation and
Application of FDHs in Enzyme Cascades
7.1. Metabolic Synthesis of Halotryptophans
While the fermentative production of canonical amino acids
such as l-glutamate and l-lysine is operated at a million-ton
scale with Corynebacterium glutamicum,[108] the fermentative
synthesis of halogenated amino acids has been reported the
first time by the group of Wendisch.[109] Metabolic engineering
of C. glutamicum resulted in a recombinant strain suitable for
the production of l-7-Cl-Trp from sugars, ammonium and
chloride salts. C. glutamicum is commonly employed for
fermentative amino acid production.[110] Its inability to use Trp
as nitrogen or carbon source or to metabolize the desired
halogenated 7-Cl-Trp, as well as the lack of Trp degrading
enzymes proved advantageous in comparison to E. coli that
degrades Trp by tryptophanase as an undesired metabolic side
pathway. After optimization of the ribosome-binding site (RBS)
of rebH, the FDH RebH was coexpressed with flavin reductase
RebF in a Trp overproducing C. glutamicum strain, finally
enabling in vivo synthesis of 7-Cl-Trp at a titer of 0.1 gL  1.
Though production was limited by product inhibition and
chlorination efficiency, strains are able to produce 7-Cl-Trp
utilizing alternative carbon sources such as arabinose and
glucosamine, that do not serve as feedstocks in human or
animal nutrition, respectively.[109] Based on these results,
Veldmann et al. subsequently addressed the fermentative
production of 7-Br-Trp.[111] Utilizing the engineered C. glutami-
cum strain enabled upscaling to a reaction volume of 2 L in a
batch and fed-batch mode resulting in significantly higher
product titers of 7-Br-Trp compared to 7-Cl-Trp (1.2 gL  1 vs.
0.1 gL  1). Though RebH is known to prefer chloride over
bromide, the inhibitory effect of 7-Br-Trp on the specific growth
rate was threefold lower than previously observed for 7-Cl-Trp.
The smaller hydration shell of 7-Cl-Trp compared to 7-Br-Trp
might facilitate its access to the active site, thus exhibiting
more pronounced inhibitory effects which finally lowers the
overall product titers.
7.2. Enzyme Immobilization and Enzyme Cascade Processes
The O’Connor group showcased that the applicability of FDHs
can be extended towards diversification of natural products in
medicinally relevant biosynthetic pathways. The integration of a
bacterial halogenase gene into a plant host was based on
preceding results indicating that Catharanthus roseus cultures
can be supplemented with halogenated tryptamines which
results in the production of haloalkaloid analogues.[112] In this
context, reengineering of strictosidine synthase (STS) catalyzing
Scheme 4. PyrH-catalyzed chlorination of l-Trp employing photochemical
regeneration of FADH2. Enzyme bound FAD is directly regenerated by
illumination for 2 min at 450 nm and usage of EDTA as a sacrificial electron
donor.
Scheme 5. Enzymatic halogenation of Trp employing NADH mimic 1-benzyl-
1,4-dihydronicotinamide (BNAH) for FADH2 regeneration. R
1=CONH2,
R2=benzyl.
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the initial step of monoterpene indole alkaloid biosynthesis
resulted in generation of STS mutants with relaxed tryptamine
specificity.[113] Thereupon, in planta production of chlorinated
alkaloids by integration of Trp-FDH into the plant metabolism
of C. roseus was reported: A suitable expression construct
containing RebH and the required reductase was transformed
into C. roseus, enabling halogenation of Trp in the plant cell.
Subsequent decarboxylation of halo-Trp by Trp decarboxylase
yielded halotryptamine which was then further processed in the
metabolic pathway to generate several novel chlorinated
alkaloids.[114]
The Sewald group successfully employed cross-linked
enzyme aggregates (CLEAs) to improve the stability of Trp
halogenases enabling regioselective bromination scalable up to
the gram scale. Ammonium sulfate precipitation of RebH
together with the auxiliary enzymes PrnF and ADH followed by
glutaraldehyde cross-linking resulted in a solid biocatalyst
performing selective halogenation with a prolonged catalyst
lifetime. l-Trp is brominated up to substrate concentrations of
200 mgL  1 with full conversion and perfect regioselectivity.[39]
The broad applicability of this methodology was subsequently
demonstrated by the Micklefield group, who also applied this
technique for other Trp halogenases such as the phenolic
halogenase RadH or the Trp 6-halogenase SttH to increase
biocatalyst efficiency in the halogenation reaction.[115] Note-
worthy, immobilization offers a convenient and straightforward
approach to obtain halogenated amino acids owing to its facile
scalability and simple downstream processing albeit achieving
low product titers compared to fermentative production of
other amino acids. Yet significant efforts are required to make
large-scale biotechnological halogenation processes feasible. In
a cascade process FDHs along with the l-specific amino acid
oxidase RebO from L. aerocolonigenes provided access to
noncanonical halogenated d-Trp analogues by dynamic stereo-
inversion (Scheme 6). d-Halotryptophans were obtained from l-
Trp by combining biocatalytic halogenation or Trp synthase
with dynamic stereoinversion in a one-pot process: Selective
oxidation of the l-enantiomer catalyzed by RebO gives rise to
the α-imino acid. Combined with an in situ reduction using a
hydride transfer agent leads to a racemic amino acid mixture.
Due to the strict l-selectivity of RebO, only the l-enantiomer is
re-oxidized, whereas the d-enantiomer gradually accumulates.
In addition to d-configured 5- or 7-bromo-/chlorotryptophans
this enzyme cascade enables the synthesis of d-7-fluoro- or 7-
iodotryptophan from substituted indoles and serine using Trp
synthase and stereoinversion, which are not accessible by Trp
halogenases.[116]
7.3. Cross-Coupling Reactions
Enzymatic halogenation introduces a handle allowing further
aryl functionalization to be performed in a one-pot manner.
Therefore, several groups sought to couple biotransformation
such as enzymatic halogenation with Suzuki-Miyaura cross-
coupling (SMC).[117–120] Pd-catalyzed cross-coupling reactions
tolerate a variety of functional groups and represent a selective
methodology to modify halogenated compounds. Especially
the formation of carbon-carbon bonds is a useful approach to
be addressed by an array of cross-coupling reactions.
Groundbreaking investigations combining Pd- and enzyme
catalysis were performed by Sato et al., demonstrating one-pot
feasibility of a Pd/Cu-catalyzed Wacker oxidation and an
enzymatic ketone reduction via compartmentalization of the
reactions employing a polydimethylsiloxane (PDMS) thimble.[121]
Building on these achievements, Latham et al. extended the
approach to a combination of enzymatic halogenation and
chemocatalysis into a sequential one-pot process. Utilizing
membrane compartmentalization enabled the combination of
FDHs with palladium-catalyzed cross-coupling in a one-pot
manner.[115] Notably, both reactions need to be conducted in a
sequential mode due to different temperature requirements.
Sharma et al. reported an in vivo approach for the generation of
a brominated natural product analogue and its subsequent
cross-coupling for diversification of halogenated natural prod-
ucts in a one-pot fashion.[122] 7-Br-Trp was generated in vivo by
engineered E. coli RG-1500 producing Trp 7-halogenase PrnA
followed by in-culture Suzuki-Miyaura cross-coupling. Further-
more, they could also demonstrate the in-culture biosynthesis
and cross-coupling of antibiotic Br-pacidamycin-D utilizing an
engineered streptomyces S. coelicolor M1154 strain. As recently
demonstrated by Gruß et al., Mizoroki-Heck reaction afforded
styryltryptophans from bromotryptophan (Scheme 7a). Biocata-
lytic halogenation of l-Trp yielded l-7-Br-Trp by making use of
the CLEA methodology. Subsequent Mizoroki-Heck coupling
employing an array of substituted styrenes and Pd(OAc)2 in the
presence of phosphine ligand trisodium 3,3’,3’’-phosphinetriyl-
tribenzenesulfonate (TPPTS) allows coupling of different alkenes
to the indole moiety via the halogen substituent. The applic-
ability of this cross-coupling reaction was further corroborated
in a sequential, three step one-pot reaction comprising
enzymatic halogenation, Mizoroki-Heck cross-coupling to water
soluble 4-carboxystyrene, followed by final Nα-Boc protection in
good overall yields up to 61%. Like the aryl substituted
tryptophans,[123] styryltryptophans exhibit a bathochromically
Scheme 6. l-Amino acid oxidase RebO can be employed to access
enantiopure halogenated d-amino acids. Biocatalytic halogenation is
followed by RebO catalyzed oxidation of the l-enantiomer to the α-imino
acid. Non-selective chemical reduction leads to the racemic amino acid, but
only the l-enantiomer is re-oxidized by RebO, leading to gradual accumu-
lation of the d-enantiomer.
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shifted absorbance and fluorescence emission compared to Trp,
thereby revealing interesting potential to serve as fluorescence
labels.[118,124] Haloarene containing amino acids (e.g. bromotryp-
tophan) constitute a versatile handle for labeling, bioorthogonal
reactions, site-selective and late-stage modification. The result-
ing biaryls obtained by SMC have been shown to possess
significant potential for studies on biological activity and drug
development.[125,126] Furthermore, Goss and coworkers reported
about a method for aqueous Heck diversification also applicable
to halotryptophans. Moreover, the transfer to a peptide based
natural metabolite derivative was successfully demonstrated.[127]
In this context Kemker et al. introduced peptide cyclization via
Suzuki-Miyaura cross-coupling (Scheme 7b). This approach was
exemplified for side chain-to-tail cyclization of RGD peptides by
applying SMC.
The halogenated amino acid was synthesized via the CLEA
methodology and introduced at the C-terminus. After synthesis
of the linear precursor peptide by solid-phase synthesis,
cyclization was carried out either on resin or in solution
between an N-terminal boronic acid and the indole ring of Br-
Trp. The resulting panel of cyclic RGD peptides, differing in size
of macrocycle, connectivity at the indole moiety (directed by
the halogen position and the boronic acid), as well as the
influence of d-amino acids and N-methylation, exhibited a
strong impact on the affinity and selectivity towards
integrins.[128] Further discussion on cascades enabling indole
functionalization can be found in a recently published review
article.[129]
8. Exploiting the Synthetic Utility of
Halogenases
8.1. Substrate Scope of WT Halogenases
Despite substantial efforts to improve in vitro compatibility of
halogenases, their large-scale application still suffers from
severe shortcomings such as enzyme stability, low activity and
their limitation to act on relatively electron rich aromatic
compounds. Initial studies on the substrate tolerance and
regioselectivity of PrnA, carried out by Hölzer et al., revealed
that strict C7-selectivity exclusively occurs for Trp.[130] Though
PrnA accepts a series of heterocyclic substrates, its regioselec-
tivity appeared more relaxed for non-native substrates. Not
surprisingly, electrophilic substitution in these cases occurred at
the electronically favored indole 3- or 2- position, sometimes
resulting in a mixture of mono and dichlorinated products.
However, Patallo et al. recently demonstrated that PrnA
regioselectively chlorinates indole-3-acetic acid at position 7,
indicating the relevance of C3 side chain for selectivity and
substrate fixation.[131] Apart from l-Trp, most of the Trp
halogenases have also been shown to catalyze chlorination of
d-Trp, albeit with preference for the native l-enantiomer.[94,132]
In contrast to the limited substrate scope of PrnA, closer
investigations on the related Trp 7-halogenase RebH indicated
a more relaxed substrate scope. RebH catalyzes halogenation of
a range of 3-substituted indoles even at electronically disfa-
vored sites and its synthetic utility was demonstrated in
preparative halogenation reactions, revealing conversion of
non-natural substrates like indole or gramine that are not
accepted by PrnA.[94] Though both halogenases exhibit high
sequence homology (55%) and nearly identical active sites,
Scheme 7. a) Derivatization of Br-Trp by Mizoroki-Heck coupling by combining bio- and chemocatalysis that is feasible in a one-pot mode. b) Stepwise
synthesis of cyclic RGD peptides. Bromination of Trp is followed by solid phase peptide synthesis (SPPS) and final cyclization via SMC carried out either in
solution or on-resin.
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RebH is more promiscuous towards other substrates rather than
Trp and retains original C7-selectivity in most cases.
A likely explanation for this altered substrate acceptance
was given by Payne et al. by aligning sites of RebH and PrnA
within 5 Å of the substrate Trp. Surprisingly, only two of the 24
analyzed residues in RebH differ in identity (N467 and L456) or
display a notable conformational change (N464 and N453)
compared to PrnA. In RebH N467 forms a water-mediated
hydrogen bond to the substrate Trp that cannot be formed by
the corresponding residue L456 in PrnA. These minor differ-
ences in the active site of RebH might be decisive to position
other substrates and to permit halogenation at electronically
disfavored sites. Furthermore, RebH displays significantly im-
proved kinetics compared to PrnA with kcat values on Trp of
1.4 min  1 vs. 0.1 min  1. Because of the low substrate conversion
by PrnA potential halogenated products might have been
missed.[94]
8.2. Influence of Directing Effects on Regioselectivity
Frese et al. further studied the influence of electron-withdraw-
ing and -donating groups at the indole ring on regioselective
halogenation employing RebH.[99] An array of C5- and C6-
substituted l-Trp derivatives was obtained from l-serine and
substituted indole derivatives using Trp synthase according to a
procedure developed by Goss et al.[133] Even in presence of
deactivating and ortho/para-directing groups, in many cases the
substrate is still halogenated at the electronically less favored
C7 position. Despite the presence of a deactivating 5-fluoro
substituent with an ortho-/para-directing effect, RebH catalyzes
halogenation at C7 position. Investigation of regioselectivity
suggested that selectivity is governed by both electronic and
steric effects. However, the binding pose of the substrate in the
active site often prevails over ortho-/para-directing effects
exerted by e.g. C5-substituents. Substrates exhibiting an
electronic preference for halogenation in ortho-position such as
5-methyl-l-Trp gave a 1 :1 mixture of derivatives chlorinated at
C6 and C7. Furthermore, bromination even dominated in C6
position and dihalogenation was also found. Docking analysis
pointed towards a slight rotation of the 5-methyl-derivative
compared to l-Trp. This suggests a binding mode in which C6
position of 5-methyl-l-Trp is directed towards the tunnel hence
overlapping with C7 from the natural substrate l-Trp. Accord-
ingly, total turnover numbers (TTN) for the chlorination of Trp
derivatives strongly depend on the steric and electronic
influence of the substrate and dropped significantly from 102
for Trp over 55 for 5-methyl-l-Trp to 7 for 5-fluoro-l-Trp,
respectively. These findings made by us and by other groups
indicate that FDHs provide a valuable platform for regioselec-
tive halogenation hardly achievable by conventional electro-
philic aromatic substitution.
8.3. Closer Investigation of Substrate Scope of FDHs
A comprehensive survey by Andorfer et al. further focused on
profiling of the substrate spectrum of several FDH’s and evolved
variants towards a broad set of arenes with different steric and
functional groups. A panel of 93 compounds was employed to
analyze FDH activity on analytical scale in a high-throughput
fashion employing LC-MS analysis. Preparative scale reactions
employing up to 10 mg substrate were purified and the
regioselectivity determined via NMR spectroscopy. Examination
of their substrate-activity profiles revealed that the substrate
scope of FDHs is less strict than initially assumed, though even
minor changes in halogenase sequence can significantly affect
specificity and scope. Both RebH and Thal exhibited activity on
a wide range of substituted anilines and indoles and were
shown to tolerate a remarkable variety of functional groups
such as for instance amines, alcohols, nitriles, esters or
sulfonamides. Moreover, the study unveiled that notable differ-
ences of the substrate profile exist among these enzymes
despite high homology, as some substrates were exclusively
and quantitatively halogenated by Thal, whereas no activity
was observed for RebH.[134] Remarkably, a RebH-4V mutant,
engineered for accepting larger indole containing compounds,
showed the broadest scope towards the tested indoles,
pyrroles, azoles, anilines and anilides. It exhibited a wider
substrate scope than the WT enzyme which demonstrated the
value of directed evolution for halogenase engineering.
Furthermore, RebH-4 V mutant also enabled desymmetrization
of prochiral methylene dianilines, thereby providing an example
of engineering the enantioselectivity of a FDH (Scheme 8).[135]
Recently, the Lewis group expanded this study to a FDH
family-wide profiling to gain deeper insight into sequence-
function information, also shedding light on enzyme activity,
halide specificity and substrate preference.[136] A BLAST search
of the UniProt sequence database identified 3975 putative
halogenase genes derived from the FDH family, covering a wide
range of sequence and host diversity, including archaeal,
eukaryotic, bacterial and viral proteins. In their survey se-
quence-similarity networks were generated to visualize func-
tional relationships among putative FDH sequences. Three sub-
networks emerged mainly differing in host domain and
compound class. FDHs natively halogenating Trp or indole
in vitro constituted the largest subnetwork, comprising 2270
sequences. The second largest subgroup (438 sequences)
contained most known phenol halogenases such as fungal
Scheme 8. Enantioselective desymmetrization of methylenedianilines. RebH-
4 V mutant catalyzes chlorination of alkyl-substituted 4,4’-methylene-
dianilines that constitutes the first example of asymmetric catalysis by FDHs
giving chiral monochlorinated product in an enantioselectivity of 99 :1.
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Rdc2 or RadH. FDHs connected to chlorination of pyrrole form
the smallest subnetwork, comprising only 212 sequences. For
functional characterization, 128 putative halogenase sequences
were codon-optimized and expressed in E. coli, resulting in a
total of 87 new enzymes obtained in a sufficient quantity of
soluble protein suitable for the following high-throughput
activity screening. Therefore, a set of 12 differing substrates,
including indoles, anilines and phenols possessing high inher-
ent reactivity were selected. Analysis of activity profiles resulted
in identification of 39 new enzymes capable of halogenating at
least one of the tested compounds, while bromination activity
prevailed over chlorination. Although the majority of FDHs
reported to date is involved in the biosynthesis of chlorinated
natural products, this survey indicates that bromination is much
more widespread in FDHs than previously assumed. Further-
more, novel and diverse FDHs capable of halogenating
complex, previously inaccessible substrates were identified.
Halogenase 1-H11, classified as an indole halogenase and
belonging to the BrvH subnetwork, is worth mentioning in this
context. In addition to improved thermal stability compared to
RebH it possesses a natural bromination activity on yohimbine,
a pharmaceutically relevant substrate that served as target
substrate in a previous substrate-walking approach of RebH
(Scheme 9).[103] The presented genome mining approach is
therefore a promising platform for future engineering ap-
proaches and might circumvent evolution of a single enzyme
by identification of related enzymes initially suitable to catalyze
a certain transformation of interest.
8.4. Halogenases Addressing Phenol-Based Substrates
Interestingly, Rdc2, a fungal phenolic FDH from Pochonia
chlamydosporia,[70] halogenates a panel of substrates poorly
accepted by Thal, RebH or evolved variants. Hydroxyisoquino-
lines and macrocyclic lactones were in most cases halogenated
in ortho-position to the hydroxy group due to its strong
directing influence. Sequence comparison of RebH and Rdc2
revealed a significant difference in primary sequence (43%
identity, 48% query coverage). Hence it is not surprising that
there is a strong difference of substrate scope between the
halogenases with Rdc2 mainly acting on phenol based
derivatives.[134,137]
RadH, another phenolic halogenase with close homology to
Rdc2 (87%), was shown by Micklefield and coworkers to
catalyze halogenation of an array of natural and synthetic
phenolic compounds. The hydroxyl functionality turned out to
be an essential motif whilst being inactive towards other
electron-rich arenes lacking the OH group. Still, RadH appeared
rather promiscuous with regard to several natural and synthetic
phenolic compounds as well as flavonoids being accepted. Its
ability to act on common pharmacophores served as a starting
point for further engineering platform for high-throughput
screening to engineer RadH variants with elevated activity for a
range of substrates which are part and contribute to antimicro-
bial activity of antibiotics as clorobiocin. Different fluorescence
properties of 7-hydroxycoumarin and its chlorinated analogue
enabled identification of a RadH double mutant exhibiting
significantly elevated activity on a range of substrates. This
evolved RadH variant was finally integrated into coumarin
Scheme 9. Directed evolution of RebH via a stepwise substrate walking approach achieved halogenation of steric demanding indole and carbazole derivatives.
a) Conversion of selected substrates determined via UPLC and mol% enzyme loading in brackets refer to the enzyme mentioned below. b) Additional
mutations identified via epPCR relative to the previous parent.
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biosynthetic pathway within recombinant E. coli, resulting in a
non-native halogenated natural product derivative produced
in vivo.[62]
9. Directed Evolution of FDHs
9.1. Expanding the Substrate Scope of FDHs by Directed
Evolution
In this context, the Lewis group pioneered in applying directed
evolution for widening the substrate scope of a Trp halogenase.
A thermostable RebH triple mutant (1-PVM), derived from a
previous evolution campaign, revealed elevated conversion of
substrates such as tryptamine and tryptoline.[103,138] Therefore,
1PVM served as a template for further rounds of random
mutagenesis to screen towards progressively larger substrates
starting from Trp to substantially larger indole-derived com-
pounds like carazolol or carvedilol. Even sterically demanding
compounds of biological interest such as the 6-chloro analogue
of deformylflustrabromine (dFBr) or α2-blocker yohimbine
(Scheme 9) could be formed from their non-halogenated
precursors. Three rounds of evolution resulted in promising
variants finally accepting a broad range of non-natural,
challenging substrates as large indoles and carbazoles that
differ significantly in terms of functionality and size to the
former native substrate Trp.[103] Furthermore, a significant
improvement of the regioselective halogenation of tryptoline
was achieved, e.g. using variant 3-SS, exhibiting 93% con-
version to the C6-chlorinated product in comparison to a 1 :1
mixture of 6- and 7-chlorotryptoline observed for the WT.
9.2. Switching Regioselectivity by Random and
Structure-Guided Mutagenesis
Lang et al. pioneered in changing the regioselectivity of Trp 7-
halogenase PrnA by structure-guided mutagenesis. The X-ray
single crystal structures of PrnA and PyrH in complex with Trp
corroborate the position of halogenation to be merely con-
trolled by the spatial orientation of the substrate relative to the
halogenating agent.
Other reactive positions of the indole moiety are shielded
by the surrounding aromatic amino acids, e.g. H101, F103 and
W455 in PrnA (Figure 4). To reduce steric demands Ala mutants
of residues located in the substrate-binding sites were
generated. Among these mutants only PrnA-F103A impacted
regioselectivity leading to a 1 :2 mixture of C5- and C7-
brominated product. The remaining preference for halogen-
ation at C7 is suggested to result from the different orientation
of the substrate that does not comply with the ideal geometry
of the active site as observed in PyrH. Presumably the mutation
allows Trp to adopt an orientation observed in a C5-halogenase
and indicates that regioselectivity is guided by surrounding
residues in the first sphere of bound Trp.[139]
A comparable approach was pursued by Shepherd et al.
who intended to switch the regioselectivity of the Trp 6-
halogenase SttH to position 5.[53] Based on structural differences
to the 5-halogenase PyrH regarding crucial amino acid residues
of the active site, point mutations were introduced replacing
specific amino acid residues of SttH by the corresponding
counterparts of PyrH. This approach resulted in less active
biocatalysts without considerable impact on regioselectivity.
However, the combination to the triple mutant SttH L460F/
P461E/P462T showed similar activity as SttH WT with relaxed
regioselectivity leading to 32% 5-Cl-Trp, whereas the wild-type
enzyme produced 6-Cl-Trp only. Noteworthy, a significant
switch in regioselectivity was observed for the more flexible
substrate 3-indolepropionic acid, yielding 75% 5-chlorinated
product in comparison to 90% 6-chlorination observed with
SttH WT.
In a detailed survey Andorfer et al. focused on random as
well as structure-guided selection of active site residues to
modify the regioselectivity of RebH.[140] Their ambition to evolve
RebH into a C5- or C6-regioselective biocatalyst led to two new
variants, 10S and 8F, capable of chlorinating tryptamine with up
to 95% regioselectivity for position 5 (variant 10S) and 90%
regioselectivity for position 6 (variant 8F). Identification of
beneficial mutations was based on up to ten generations of
mutagenesis and high-throughput screening including random,
site-directed as well as site-saturation mutagenesis. Therefore,
the development of a high-throughput screening assay was
initially necessary to identify halogenase variants with altered
regioselectivity. Deuterated tryptamine that is more easily
accessible than the corresponding Trp was synthesized and
served as a probe to identify a switch of regioselectivity by MS-
based screening. Mutants with altered selectivity towards
deuterotryptamine could be identified owing to the mass shift
of Δm/z=1 caused by the deuterium in the molecule once a
position other than C–D site is being halogenated. As the
MALDI-TOF MS assay employed was based on deuterated
tryptamine, the results were valid for tryptamine only, but not
for the native substrate Trp. While recognizing this remarkable
achievement, it should be pointed out that tryptamine is a less
bulky substrate than Trp due to the lack of the carboxy-group.
This leads to higher flexibility in the active site upon binding to
the halogenase, which might facilitate the substrate to adopt a
different binding pose which is beneficial to swap the
regioselectivity.
Recently Moritzer et al. demonstrated the generation of a
non-natural Trp 7-halogenase (Thal-RebH5) by mutating five
active-site residues of Thal to the corresponding counterparts
of RebH.[57] An impressive shift of 95% in regioselectivity
towards C7-halogenation for both chlorination and bromination
of Trp was achieved by site-directed mutagenesis simply by
altering five amino acid residues based on rational design
(Scheme 10). The resulting quintuple mutant exhibited a nearly
quantitative switch in regioselectivity for halogenation of its
native substrate Trp that has not been reported for another Trp
halogenase so far.
ChemCatChem
Reviews
doi.org/10.1002/cctc.202000531
4465ChemCatChem 2020, 12, 4450–4470 www.chemcatchem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Freitag, 11.09.2020
2018 / 173127 [S. 4465/4470] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
10. Engineering of Thermostability and
Increased Activity
As for many other enzymes from secondary metabolism, FDH’s
are not essential for any metabolic functions related to survival
or growth of its main host. Therefore, higher affinities and
turnover rates did not evolve due to lower evolutionary
pressure compared to enzymes involved in central metabolism
and the host’s own requirement of Trp for protein
biosynthesis.[141]
Characterization of FDH kinetic parameters revealed that
in vitro halogenation is a rather inefficient reaction and their
low activity and instability currently exclude their employment
in vitro for large scale synthetic applications (Table 3). Although
enzyme immobilization as cross-linked enzyme aggregates
increases productivity owing to a higher lifetime and simplified
biocatalyst recycling and removal, biotechnological application
of FDH is still limited to analytical and semipreparative scale.
10.1. High-Throughput Assays to Evaluate Halogenase
Activity in Directed Evolution
Any attempt for discovering or engineering of halogenases
requires the capacity to detect and quantify enzyme activity in
a facile and rapid manner. Regarding directed evolution, one of
the most important and at the same time limiting factors is a
reliable and rapid high-throughput screening assay to identify
the desired mutants. High-performance liquid chromatography
(HPLC) is considered as a standard to assay halogenase activity
in kinetic analysis as well as in directed evolution. Despite being
a universal technique with few limitations, such assays of
biocatalytic reactions are usually very time-consuming and rely
on specialized equipment such as ultra-high-performance liquid
chromatography (uHPLC) instruments. Distinct differences of
UV-vis absorbance spectra between halogenated anilines and
their non-halogenated precursor molecules provided the basis
for the development of a colorimetric assay capable of
monitoring halogenation of different arylamines in a microtiter
plate (Scheme 11). Hosford et al. described a rapid high-
throughput assay in aqueous solution based on the in situ
oxidation of 4-methylcatechol by horseradish peroxidase (HRP)
to the corresponding ortho-benzoquinone. Subsequent Michael
addition of the quinone to either the halogenated or non-
halogenated arylamine leads to the formation of the desired
ortho-benzoquinone-amine adduct.[143] The assay was coupled
to halogenase RebH and confirmed reliable discrimination
between the substrate and the halogenated product for several
arylamines even in presence of further functionalities. Yet, this
one-pot workflow needs to be quenched by heat-precipitation
before HRP, H2O2 and 4-methylcatechol could be added to
enable formation of the probe of interest. Unfortunately, the
required presence of an arylamine functionality restricts the
assay to a limited number of halogenase substrates and its
application has not yet been demonstrated for directed
evolution.
Another colorimetric high-throughput assay to detect
halogenase activity was based on the specific l-amino acid
oxidase RebO owing to the high specificity for halotryptophan
compared to Trp. Release of H2O2 per equivalent of amino acid
oxidized allows for quantification via coupling to HRP leading
to concentration dependent dye formation. Yet the applicability
of this assay was not demonstrated in a directed evolution
campaign.[116]
In this context, Schnepel et al. developed a fluorescence
assay based on Suzuki-Miyaura cross-coupling appropriate for
high-throughput screening to quantify the halogenation activity
of Trp 5-, 6- and 7-halogenases.[123] Coupling of 3-amino-
phenylboronic acid and the brominated amino acid provided
the basis to monitor quantitative formation of Br-Trp due to
superior fluorescence properties of the coupling product
compared to Trp and Br-Trp (Scheme 12). This robust activity
assay applicable in microtiter plates is directly performed in
crude E. coli lysate and enables high-throughput screening of
large mutant libraries without requiring purification steps or a
Scheme 10. Change of halogenase selectivity by structure-guided muta-
genesis. Thal-RebH5-catalyzed halogenation yields l-7-halotryptophan as the
dominant regioisomer, thus introducing strict C7-selectivity into Thal. X=Cl,
Br.
Table 3. Kinetic parameters of Trp halogenases with l-Trp as substrate.
Reaction temperature is given in brackets if specified.
Trp halogenase kcat [min
  1] KM [μM] Reference
PrnA 0.1 (30 °C) 160 Dong et al., 2005[51]
PyrH 0.5 (30 °C) 150 Zehner et al., 2005[36]
RebH 1.4 2.0 Yeh et al., 2005[35]
Thal 2.8 110 Seibold et al., 2006[142]
Th-Hal 4.3 (30 °C) 12.2 Menon et al., 2016[41]
BorH 4.4 (45 °C) 9.8 Lingkon et al., 2019[43]
Scheme 11. UV-Vis based high-throughput screening for detection of
halogenase activity. RebH-catalyzed halogenation of an aryl amine is
followed by in situ oxidation of 4-methylcatechol and formation of the
halogenated quinone-amine adduct that can be traced spectrophotometri-
cally due to a shift of the absorbance maxima.
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specialized laboratory equipment. Though this assay was
optimized for coupling of 5-, 6-, and 7-bromotryptophan to 3-
aminophenylboronic acid, the high specificity also limits the
simple transfer to other substrates and requires previous
calibration with a suitable standard. Still, this activity assay
enabled identification of a thermostable Thal variant (Thal-GR)
comprising mutations S359G/K374R, which exhibits a signifi-
cantly increased thermostability and 2.5-fold improved activity
compared to the WT enzyme.[123]
Based on these achievements obtained from the first round
of Thal evolution Minges et al. focused on a more comprehen-
sive evolution campaign to further improve its thermostability
and catalytic performance.[132] Fluorogenic high-throughput
screening enabled identification of significantly more thermo-
stable Thal variants harbouring three to five mutations, mainly
being located at the interface to the second Thal monomer. The
individual mutation’s impact on thermostability and activity
was analyzed in detail, revealing that mutation S359G tremen-
dously increases thermostability and activity although being
located in the active site. Noteworthy, this Ser residue,
conserved among Trp-FDHs, also increases enantiomer selectiv-
ity giving significantly reduced conversion of d-Trp. In addition
to an unexpected role of this residue in substrate acceptance,
activity and thermostability, native ESI-MS analysis also revealed
an enhanced tendency for dimer formation of selected Thal
variants compared to the WT enzyme suggesting that dimeriza-
tion favors halogenase stabilization. Finally, combination of
different evolution strategies including directed evolution,
rational design as well as site-saturation mutagenesis led to a
Thal triple mutant (Thal-GLV) exhibiting significantly increased
thermostability compared to Thal WT (~T50=16.0 K; ~TM=
23.5 K) and strongly elevated enzyme activity at 25 °C.
10.2. Increasing Halogenase Stability
Menon et al., aimed at identifying and employing a thermo-
philic Trp halogenase as a productive and robust biocatalyst
exhibiting improved catalytic activity and stability compared to
other FDHs.[41] Th-Hal from Streptomyces violaceusniger strain
SPC6 along with a thermophilic flavin reductase Th-Fre from
Bacillus subtilis WU-S2B provided a thermostable halogenation
system and enabled quantitative halogenation of Trp at C6
position. At 30 °C Th-Hal was more active towards Trp than any
other halogenase tested and determination of melting temper-
ature by CD spectroscopy revealed a 10 K elevated TM
compared to other mesophilic Trp halogenases. Comparison of
Th-Hal with other Trp halogenases in combination with thermo-
stable reductase also showed that combination of Th-Hal/Th-
Fre afforded significantly higher conversion of Trp at 40 °C. In
addition, substrate specificity and regioselectivity resembles
that of the Trp 6-halogenase SttH sharing 76.2% sequence
identity to each other.[53] Interestingly, a closer look into amino
acid variations between Th-Hal and SttH revealed most
variations occurring on the protein surface. Mainly polar
residues were present that impact hydrogen bonds on the
surface and probably prevent deleterious protein aggregation.
Moreover, retention of activity and more robustness in polar
organic solvents compared to SttH underline that thermophilic
enzymes provide a promising and robust halogenating system
for future engineering approaches. These findings made for Th-
Hal may provide a promising starting point to modify or mutate
a protein’s surface to retain catalytic activity and elevate
enzyme stability.
Likewise, Lingkon et al. closely characterized and crystallized
Trp 6-halogenase BorH and its accompanying flavin reductase
BorF derived from a desert soil sample.[43] BorH exhibits slightly
higher thermostability than the majority of Trp 6-halogenases,
possessing a TM of 48 °C and operating at a Topt of 45 °C
compared to a Topt of 25–30 °C for Thal (TM=47.7 °C),
[132] Topt of
40 °C for SttH[40] or a TM of 47.8 °C for Th-Hal.
[41] First preparative
scale chlorination of 100 mg Trp employing 0.2 mol% BorH
along with BorF yielded 52% chlorinated product, rendering
both enzymes interesting for industrial scale bioconversion.
BorH’s capability of halogenating a broad range of aromatic
compounds and exhibiting altered activities on substrates
previously observed for other Trp-6 halogenases underline its
value as promising biocatalyst or template for further evolution
studies.
Poor et al. also focused on improving the thermostability of
mesophilic Trp halogenases. Three rounds of mutagenesis
resulted in a thermostable RebH variant (3-LSR) exhibiting a
significant increase in enzyme stability as evident by a rise of
the melting temperature (TM) of 18 K compared to the WT
enzyme. Furthermore, the optimum reaction temperature (Topt)
increased from 30–35 °C to 40 °C for selected mutants (3-LR). In
addition to an increased conversion of Trp, improved con-
version was also reported for unnatural substrates such as
tryptoline or 2-methyltryptamine. However, despite increased
temperature tolerance and higher lifetime its catalytic efficiency
at 21 °C was reduced whereas a higher product yield resulted
from a longer lifetime thus compensating its lower catalytic
activity.[138]
11. Summary and Outlook
Despite recent achievements to broaden the application scope
of FDH by means of protein engineering, further efforts are
required to provide robust enzymes capable of large-scale C-H-
functionalization that can be accomplished in multistep syn-
thesis and reaction cascades. However, promising results have
Scheme 12. Formation of a fluorescent biaryl resulting from derivatization of
halogenated Trp by Suzuki-Miyaura reaction provides the basis for a high-
throughput assay to monitor activity of Trp halogenases.
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been achieved by means of directed evolution and enzyme
discovery. Protein engineering especially succeeded in expand-
ing the substrate scope as well as improving stability and
activity. As the frequent lack of compatibility of bio- and
chemocatalysis cannot be neglected, further efforts are required
to overcome this drawback. In light of developing novel
approaches for enzymatic halogenation many steps have to be
undertaken to replace conventional chemistry still being
superior in terms of reaction scale and application range. Thus,
the low productivity of halogenating enzymes has to be
overcome for obtaining higher product titers. Presumably,
future developments in reaction engineering, flow catalysis, and
enzyme engineering will foster progress on large-scale enzy-
matic halogenation. FDHs seem to prefer electron-rich aro-
matics such as indoles and phenols. Halogenation of more
electron-deficient substrates will make an important contribu-
tion. In particular, the discovery of novel halogenases applying
bioinformatic tools along with rational protein design and
broad substrate scoping will considerably streamline the
progress towards more generic tools for selective C  H
activation.
Owing to enormous genome data availability, ongoing
progress in computer-based engineering and the growing
demand for sustainable and environmentally friendly fine-
chemical synthesis this versatile enzyme class should not be
neglected as it expands the horizon towards possible future
applications.
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